MediciNova MN-001 Trial Misses Primary Endpoints; ALS Results Expected Year-End

MediciNova said its small Phase 2 trial of MN-001 in NAFLD with hypertriglyceridemia missed primary endpoints, though HDL-C and HDL-P improved and early triglyceride reduction was significant. Topline results from the COMBAT-ALS Phase 2b/3 trial of MN-166 are expected by year-end.